Last reviewed · How we verify

Enhanced ALPP CAR-T treatment

TCRCure Biopharma Ltd. · Phase 1 active Biologic

Enhanced ALPP CAR-T treatment is a Biologic drug developed by TCRCure Biopharma Ltd.. It is currently in Phase 1 development. Also known as: Fludarabine Cyclophosphamide.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameEnhanced ALPP CAR-T treatment
Also known asFludarabine Cyclophosphamide
SponsorTCRCure Biopharma Ltd.
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Enhanced ALPP CAR-T treatment

What is Enhanced ALPP CAR-T treatment?

Enhanced ALPP CAR-T treatment is a Biologic drug developed by TCRCure Biopharma Ltd..

Who makes Enhanced ALPP CAR-T treatment?

Enhanced ALPP CAR-T treatment is developed by TCRCure Biopharma Ltd. (see full TCRCure Biopharma Ltd. pipeline at /company/tcrcure-biopharma-ltd).

Is Enhanced ALPP CAR-T treatment also known as anything else?

Enhanced ALPP CAR-T treatment is also known as Fludarabine Cyclophosphamide.

What development phase is Enhanced ALPP CAR-T treatment in?

Enhanced ALPP CAR-T treatment is in Phase 1.

Related